Statins and infrainguinal vascular bypass procedures

Current Vascular Pharmacology

Volumn 11, Issue 1, 2013, Pages 51-57

  Paraskevas, Kosmas I ^a   Giannoukas, Athanasios D ^b   Mikhailidis, Dimitri P ^c  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Infrainguinal bypass graft operation perioperative mortality and morbidity; Peripheral arterial disease; Peripheral endovascular procedures; Statins

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

AMPUTATION; BYPASS SURGERY; CARDIOVASCULAR MORTALITY; DRUG MEGADOSE; FOLLOW UP; GRAFT OCCLUSION; GRAFT PATENCY; GRAFT STENOSIS; HUMAN; HYPERCHOLESTEROLEMIA; INFRAINGUINAL BYPASS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL MORTALITY;

EID: 84873196353     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113804547610     Document Type: Review

References (60)

1. Paraskevas KI, Hamilton G, Mikhailidis DP. Statins: An essential component in the management of carotid artery disease. J Vasc Surg 2007; 46(2): 373-386.
2. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Are statins an option in the management of abdominal aortic aneurysms? Vasc Endovascular Surg 2008; 42(2): 128-134.
3. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008; 6(4): 237-239.
4. Paraskevas KI, Bessias N, Perdikides TT, Mikhailidis DP. Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin 2009; 25(7): 1807-1809.
5. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32(3): 286-293.
6. Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 2006; 20(5): 696-705.
7. Falluji N, Mukherjee D. Contemporary management of infrapopliteal peripheral arterial disease. Angiology 2011; 62(6): 490-499.
8. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008; 47(4): 774-781.
9. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55(1): 53-62.
10. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336(3): 153-162.
11. Aggressive lipid-lowering therapy beneficial after bypass grafting, say researchers. Am J Health Syst Pharm 1997; 54(6): 626.
12. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000; 36(5): 1691-1697.
13. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36(1): 150-157.
14. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002; 30(2): 120-126.
15. Corpataux JM, Naik J, Porter KE, London NJ. A comparison of six statins on the development of intimal hyperplasia in a human vein culture model. Eur J Vasc Endovasc Surg 2005; 29(2): 177-181.
16. Henke PK, Blackburn S, Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004; 39(2): 357-365.
17. Abbruzzese TA, Havens J, Belkin M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39(6): 1178-1185.
18. Fujita H, Banno H, Yamanouchi D, Kobayashi M, Yamamoto K, Komori K. Pitavastatin inhibits intimal hyperplasia in rabbit vein graft. J Surg Res 2008; 148(2): 238-243.
19. Hata M, Takayama T, Sezai A, Yoshitake I, Hirayama A, Minami K. Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. Ann Thorac Surg 2009; 88(5): 1440-1444.
20. Jie Li, Lu WM, Li XX, et al. Intensive statin therapy: a favorable adjunct to the improvement of small-diameter vascular grafts. Angiology 2010; 61(5): 427-436.
21. Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104(3): 264-268.
22. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005; 42(3): 456-464.
23. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107(14): 1848-1851.
24. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. J Am Coll Cardiol 2005; 45(3): 336-342.
25. Desai H, Aronow WS, Ahn C, et al. Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. Arch Gerontol Geriatr 2010; 51(2): 149-151.
26. Welten GM, Chonchol M, Schouten O, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant 2008; 23(12): 3867-3873.
27. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22(1): 118-127.
28. Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver function tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a posthoc analysis. Lancet 2010; 376(9756): 1916-1922.
29. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007; 11(9): 1143-1160.
30. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets 2011; 15(4): 401-20.
31. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heartdisease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20(5): 627-637.
32. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15(5): 479-489.
33. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study, 1984 to 1992. Circulation 1999; 99(2): 237-242.
34. Danesh J, Whincup P, Walker M, Lennon et al. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321(7255): 199-204.
35. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12): 836-843.
36. Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin 2008; 24(1): 75-78.
37. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100(3): 230-235.
38. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103(9): 1191-1193.
39. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353(9157): 983-984.
40. Ikeda U, Shimada K. Statins and monocytes. Lancet 1999; 353(9169): 2070.
41. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7(6): 687-692.
42. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6(12): 1399-1402.
43. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003; 163(15): 1837-1841.
44. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274(31):21926-21931.
45. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83(5): 490-500.
46. Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitolios AI. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis 2010; 211(1): 9-14.
47. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80(7): 1095-1100.
48. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97(12): 1129-1135.
49. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273(37): 24266-24271.
50. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95(15): 8880-8885.
51. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108(3): 399-405.
52. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108(3): 391-397.
53. Walter DH, Rittig K, Mahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105(25): 3017-3024.
54. Dangas G, Smith DA, Unger AH, et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83(5): 688-692.
55. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20(2): 556-562.
56. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83(7): 683-690.
57. Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg 2010; 51(4): 869-877.
58. Hoeks SE, Scholte op Reimer WJ, van Gestel YR, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes 2009; 2(4): 338-343.
59. Carter A, Murphy MO, Halka AT, et al. The natural history of stenoses with lower limb arterial bypass grafts using a graft surveillance system. Ann Vasc Surg 2007; 21(6): 695-703.
60. Health Warehouse. Available at: http://www.healthwarehouse.com/simvastatin-80mg-tablets.html and http://www.healthwarehouse. com/simvastatin-40mg-tablets.html.